AstraZeneca struck a large AI-enabled target-discovery collaboration with insitro focused on liver and heart disease programs. The deal underscores how large pharmas are formalizing partnerships to outsource earlier-stage target identification to machine-learning systems backed by experimental validation. The financing terms reported for the collaboration include a $1.5 billion agreement for AI-enabled work, reflecting AstraZeneca’s appetite to integrate structured discovery workflows with insitro’s model-and-lab iteration. For insitro, the partnership provides substantial non-dilutive runway for expanding its platform deliverables. Executives at both sides are effectively betting that AI can improve the throughput and quality of early target selection, while drug developers and CROs coordinate around assay design, data generation, and “translation-to-candidate” constraints. The transaction also signals where budgets are shifting inside pharma: away from narrow technology pilots and toward platform commitments tied to specific therapeutic area targets and deliverables.